Abstract

Pseudorabies virus (PRV) is an alphaherpesvirus that causes pseudorabies (PR), an economically important viral disease of pigs. Marker vaccines were widely used in PR prevention and eradication programs. The purpose of this study was to construct a novel recombinant virus with deletions at defined regions in the glycoprotein E (gE) and thymine kinase (TK) genes by homologous recombination. This study also evaluated the safety and efficacy of the virus for a live attenuated marker vaccine. No significant difference was observed in virus replication between gE gene-deleted (gE−), gE/TK double gene-deleted (gE−TK−), and wild-type PRV by growth curve analysis. However, gE−TK− PRV was completely attenuated in mice. To evaluate the immunogenicity of gE−TK− PRV, four 12-week-old specific-pathogen-free pigs per group were immunized intramuscularly with viral titers of 1×104, 1×105, or 1×106 TCID50, followed by intranasal challenge infection with virulent PRV (1×108 TCID50) at 3 weeks post vaccination. The gE−TK− PRV-vaccinated pigs displayed no general adverse effects after immunization and had protective immune responses after PRV challenge. Thus, gE−TK− PRV was safe and efficacious and might be a potential candidate for a live attenuated marker vaccine against PRV.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.